Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282930 · ClinicalTrials.gov registry record · Phase 3
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
A Phase 3 study of Proteinuria and Progressive IgA Nephropathy, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT02282930: Completed Phase 3 study of Proteinuria and Progressive IgA Nephropathy, sponsored by Mayo Clinic.
NCT02282930 is a Phase 3 study of Proteinuria and Progressive IgA Nephropathy that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 204-participant average among 10 other Proteinuria trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02282930, a Phase 3 study of Proteinuria and Progressive IgA Nephropathy, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.
Primary Outcome
A complete response is defined by \<300 mg proteinuria/24 hours and no greater than a 10% reduction in glomerular filtration rate (GFR) as determined by quantified creatinine clearance. A partial response is defined by \>50% reduction in 24 hour proteinuria and no greater than a 25% reduction in baseline GFR as quantified creatinine clearance. No response is defined by \< or equal to 50% reduction, unchanged or increasing proteinuria over baseline levels and a greater than a 25% reduction in b
Conditions Studied
Interventions
- DRUG ACTH (Acthar) Gel
Study Locations (4)
California
- Stanford University - Palo Alto
Florida
- Mayo Clinic Jacksonville - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-06-30 |
| Phase | Phase 3 |
What the finished NCT02282930 record still lists
NCT02282930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 204-participant average among 10 other Proteinuria trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Proteinuria appearing as the primary indexed condition, and to 1 intervention - of which ACTH (Acthar) Gel is the first listed.
NCT02282930 reports a single indexed study location in California, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02282930 about?
NCT02282930 is a clinical study titled "Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression". This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.
What is the current status of trial NCT02282930?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2015-03. Estimated completion is 2018-06-30.
What conditions does trial NCT02282930 study?
This clinical trial studies the following conditions: Proteinuria, Progressive IgA Nephropathy.
What interventions are being tested in trial NCT02282930?
The interventions under investigation include: ACTH (Acthar) Gel (DRUG).
Who is sponsoring clinical trial NCT02282930?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02282930 being conducted?
This trial has 4 study locations across California, Florida, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02282930's enrollment target sits among peer trials
20 8th of 10 higher than 2 of 10 other Proteinuria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Proteinuria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
COMPLETED · Phase 3
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Proteinuria in Pre and Post Transplant
RECRUITING
-
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia